R. You

1.7k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

R. You is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, R. You has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Dermatology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in R. You's work include Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (11 papers) and Autoimmune Bullous Skin Diseases (7 papers). R. You is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (11 papers) and Autoimmune Bullous Skin Diseases (7 papers). R. You collaborates with scholars based in Switzerland, China and United States. R. You's co-authors include M. Milutinovic, Kristian Reich, Sophie Hugot, Diamant Thaçi, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Andrew Blauvelt, Michael Ziv and Andreas Pinter and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

R. You

15 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by R. You

Since Specialization

Citations

This map shows the geographic impact of R. You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. You more than expected).

Fields of papers citing papers by R. You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. You. The network helps show where R. You may publish in the future.

Co-authorship network of co-authors of R. You

This figure shows the co-authorship network connecting the top 25 collaborators of R. You. A scholar is included among the top collaborators of R. You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. You. R. You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies 2023 ·Clinical and Experimental Dermatology ·Mark Lebwohl, Lars Iversen, Liv Eidsmo, James G. Krueger, Mayte Suárez‐Fariñas, Lewis E. Tomalin, Frank Kolbinger, R. You, M. Milutinovic	10
2	Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials 2022 ·British Journal of Dermatology ·Richard G. Langley, Howard Sofen, (unknown), Kristian Reich, Bárður Sigurgeirsson, Richard B. Warren, C. Paul, Jacek C. Szepietowski, Tsen‐Fang Tsai, Isabelle Hampele, R. You, Pascal Charef, C. Papavassilis	27
3	Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control 2021 ·Clinical Pharmacology & Therapeutics ·R. You, Sebastian Weber, (unknown), Marc Vandemeulebroecke	1
4	25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year 2021 ·Journal of the American Academy of Dermatology ·Christine Bodemer, Andrzej Kaszuba, Külli Kingo, (unknown), Akimichi Morita, Enrique Rivas, P. Papanastasiou, Manmath Patekar, C. Papavassilis, Gerard Bruin, R. You	1
5	A study of the drug secukinumab in the treatment of palmoplantar psoriasis 2020 ·British Journal of Dermatology ·A.B. Gottlieb, А. А. Кубанов, Martijn B. A. van Doorn, John Sullivan, Kim Papp, R. You, P. Regnault, Jennifer Frueh	0
6	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study* 2020 ·British Journal of Dermatology ·Kristian Reich, John Sullivan, Petr Arenberger, S. Jazayeri, Ulrich Mrowietz, Matthias Augustin, Boni E. Elewski, R. You, P. Regnault, Jennifer Frueh	41
7	Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE , a randomized, double‐blind, placebo‐controlled trial 2019 ·British Journal of Dermatology ·Alice B. Gottlieb, А. А. Кубанов, Martijn B. A. van Doorn, John Sullivan, Kim Papp, R. You, P. Regnault, Jennifer Frueh	27
8	Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment 2018 ·SKIN The Journal of Cutaneous Medicine ·(unknown), Kristian Reich, (unknown), Andrew Blauvelt, (unknown), (unknown), R. You, (unknown), M. Milutinovic, C.E.M. Griffiths	1
9	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial 2018 ·British Journal of Dermatology ·Kristian Reich, John Sullivan, Petr Arenberger, Ulrich Mrowietz, S. Jazayeri, Matthias Augustin, (unknown), P. Regnault, R. You, M. Milutinovic	76
10	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study 2017 ·British Journal of Dermatology ·Robert Bissonnette, Thomas A. Luger, Diamant Thaçi, D. Toth, I. Messina, R. You, Adriana Guana, T. Fox, C. Papavassilis, I. Gilloteau, Ulrich Mrowietz	55
11	Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial 2016 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, John Sullivan, Martijn B. A. van Doorn, А. А. Кубанов, R. You, (unknown), Sophie Hugot, M. Milutinovic	110
12	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study 2016 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, Stephen K. Tyring, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, R. You, M. Milutinovic, Diamant Thaçi	231
13	Supériorité du sécukinumab sur l’ustékinumab dans le psoriasis en plaques modéré à sévère de l’adulte : résultats de l’étude CLEAR à 1 an 2016 ·Annales de Dermatologie et de Vénéréologie ·J.‐P. Lacour, M. Ruer‐Mulard, A. Khemis, M. Beylot‐Barry, P. Celérier, Andrew Blauvelt, Kristian Reich, (unknown), Stephen K. Tyring, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, R. You, M. Milutinovic, (unknown), Lucie Martin, Diamant Thaçi	0
14	FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study 2016 ·Annals of the Rheumatic Diseases ·Kristian Reich, John Sullivan, Petr Arenberger, Ulrich Mrowietz, S. Jazayeri, Matthias Augustin, (unknown), P. Regnault, R. You, M. Milutinovic	12
15	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial breakdown → 2015 ·Journal of the American Academy of Dermatology ·Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic	429
16	Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) 2014 ·Journal of the European Academy of Dermatology and Venereology ·C. Paul, J.‐P. Lacour, (unknown), (unknown), S. Jazayeri, Stewart Adams, (unknown), R. You, C. Papavassilis, (unknown)	237
17	Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-β1 gene expression and protein production 1999 ·Journal of Vascular Surgery ·Peter J. Pappas, R. You, Pranela Rameshwar, (unknown), David O. DeFouw, Courtney K. Phillips, Frank T. Padberg, Michael Silva, Gregory Simonian, Robert W. Hobson, Walter N. Durán	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact